Wall Street Zen Downgrades Haemonetics (NYSE:HAE) to Hold

Haemonetics (NYSE:HAE) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Sunday.

A number of other brokerages have also recently issued reports on HAE. Barrington Research lifted their price target on shares of Haemonetics from $86.00 to $90.00 and gave the company an “outperform” rating in a research report on Friday, November 7th. Needham & Company LLC raised their target price on shares of Haemonetics from $68.00 to $78.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Citigroup dropped their price target on Haemonetics from $78.00 to $64.00 and set a “buy” rating on the stock in a research report on Tuesday, October 7th. Weiss Ratings restated a “hold (c-)” rating on shares of Haemonetics in a research note on Monday, December 8th. Finally, Raymond James Financial reiterated an “outperform” rating and set a $90.00 price objective on shares of Haemonetics in a research note on Friday, November 14th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Haemonetics has a consensus rating of “Moderate Buy” and a consensus target price of $82.10.

Haemonetics Price Performance

Shares of HAE stock opened at $80.44 on Friday. The stock has a market cap of $3.77 billion, a price-to-earnings ratio of 23.52, a PEG ratio of 1.58 and a beta of 0.29. The business’s fifty day moving average is $65.99 and its 200 day moving average is $64.49. Haemonetics has a twelve month low of $47.31 and a twelve month high of $87.32. The company has a quick ratio of 1.03, a current ratio of 1.64 and a debt-to-equity ratio of 1.08.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.27 EPS for the quarter, beating the consensus estimate of $1.12 by $0.15. Haemonetics had a return on equity of 27.22% and a net margin of 12.67%.The business had revenue of $327.32 million during the quarter, compared to analyst estimates of $311.61 million. During the same quarter last year, the firm posted $1.12 earnings per share. The company’s revenue for the quarter was down 5.3% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. Research analysts expect that Haemonetics will post 4.55 EPS for the current fiscal year.

Hedge Funds Weigh In On Haemonetics

Several hedge funds and other institutional investors have recently bought and sold shares of HAE. AQR Capital Management LLC boosted its holdings in shares of Haemonetics by 372.8% during the 3rd quarter. AQR Capital Management LLC now owns 2,128,878 shares of the medical instruments supplier’s stock valued at $102,814,000 after acquiring an additional 1,678,630 shares during the last quarter. River Road Asset Management LLC lifted its position in Haemonetics by 18.7% during the second quarter. River Road Asset Management LLC now owns 1,655,676 shares of the medical instruments supplier’s stock valued at $122,586,000 after purchasing an additional 260,624 shares during the period. Geode Capital Management LLC lifted its position in Haemonetics by 1.9% during the second quarter. Geode Capital Management LLC now owns 1,244,624 shares of the medical instruments supplier’s stock valued at $92,873,000 after purchasing an additional 23,257 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Haemonetics by 2.5% in the third quarter. Dimensional Fund Advisors LP now owns 1,099,519 shares of the medical instruments supplier’s stock worth $53,587,000 after purchasing an additional 26,763 shares during the last quarter. Finally, Royal Bank of Canada grew its position in Haemonetics by 2.3% in the 1st quarter. Royal Bank of Canada now owns 1,075,604 shares of the medical instruments supplier’s stock worth $68,355,000 after purchasing an additional 24,650 shares during the period. Institutional investors own 99.67% of the company’s stock.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.